Literature DB >> 8819255

Three different cell types can synthesize factor XIII subunit A in the human liver.

R Adány1, M Antal.   

Abstract

The origin of human Factor XIII subunit A (FXIII A) has been a subject of intense speculation and investigation during the last decade. The major question under dispute is whether hepatocytes can produce this clotting factor. Experimental evidence obtained by FXIII A phenotype analysis in bone marrow transplant patients clearly identified hemopoietic cells (monocytes/macrophages and/or megakaryocytes/ platelets) as a source of FXIII A, and also showed that additional extra-hemopoietic site(s) of synthesis also exist. The liver has been suggested as a possible extra-hemopoietic source of plasma FXIII A, but the cells responsible for synthesizing FXIII A were not identified yet. Our present study was designed to determine the cellular distribution of both FXIII A and its encoding mRNA in human liver samples by using light- and electron-microscopic immuno-morphological and in situ hybridization techniques. In paraformaldehyde/glutaraldehyde (PA/GA) fixed, araldite-embedded semithin sections that were immunostained by an ABC/DAB based postembedding immunocytochemical method, FXIII A could be detected in Kupffer cells, connective tissue histiocytes and hepatocytes. Immunoreactive hepatocytes were observed almost exclusively around the venae centrales. By using postembedding immunogold labeling, FXIII A could be electron-microscopically visualized in these hepatocytes in the immediate vicinity of the lamellae of the endoplasmic reticulum. By in situ hybridization using a mixture of five 32-40mer biotinylated oligonucleotides (ONs) to mRNA regions encoded by exons VI, XI and XV and a labeling system containing streptavidin conjugated with alkaline phosphatase/BCIP/NBT, the message for FXIII A could be detected in the same cell types. These results show that in human liver three different types of cells can synthesize FXIII A, but the extent of their contribution to the plasma FXIII A level will require further studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8819255

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

Review 1.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

2.  Identification of a FXIIIA variant in human neuroblastoma cell lines.

Authors:  Martina lannaccone; Gaia Giuberti; Giulia De Vivo; Michele Caraglia; Vittorio Gentile
Journal:  Int J Biochem Mol Biol       Date:  2013-07-29

3.  Airway factor XIII associates with type 2 inflammation and airway obstruction in asthmatic patients.

Authors:  Stephane Esnault; Elizabeth A Kelly; Ronald L Sorkness; Michael D Evans; William W Busse; Nizar N Jarjour
Journal:  J Allergy Clin Immunol       Date:  2015-10-30       Impact factor: 10.793

4.  Use of coagulation factor XIII (F13) gene as an internal control for normalization of genomic DNA's for HLA typing.

Authors:  Anupama Cheleri Neduvat; Prerana Madhusudhana Murthy; Sudarson Sundarrajan; Sriram Padmanabhan
Journal:  MethodsX       Date:  2018-08-03

5.  Monocytes Expose Factor XIII-A and Stabilize Thrombi against Fibrinolytic Degradation.

Authors:  Fahad S M Alshehri; Claire S Whyte; Ahmet Tuncay; Maria-Louise Williams; Heather M Wilson; Nicola J Mutch
Journal:  Int J Mol Sci       Date:  2021-06-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.